Research pipeline
We combine the pioneering science of our collaborators with the recognised expertise of our core partners. Together, we are advancing a pipeline of potential first-in-class or best-in-class, child-focused therapeutic assets to address some of the most challenging indications in paediatric cancer.
CF-012
A potential first-in-class, ETV6 inhibitor for the treatment of Ewing sarcoma
In collaboration with:
University of Virginia
Dana-Farber Cancer Institute
Mass General Brigham
CF-033
A potential first-in-class allogeneic, PRAME-targeting iNKT cell therapy to treat advanced cancers in young patients
In collaboration with:
MiNK Therapeutics
University of Southampton
Work with us
Whether you’re a researcher with a therapeutic opportunity, a potential partner or an impact investor, we want to hear from you.
Research collaborations
Are you a research team, with a promising validated target in paediatric cancer? Our next deadline for expressions of interest is 4 September 2026.
Learn more
Partnering & investment opportunities
Are you an investor, or interested in partnering opportunities?
Explore partnering
News and events
We are creating a consortium united in the unwavering belief that we can challenge conventional approaches and accelerate translation of promising ideas into new therapies for children and young people affected by cancer.
Stay up to date on our latest news, events and research.
A little hero's journey: our duty to deliver
John Rainsbury on his son Will's cancer journey and the hope that new paediatric research might bring to children affected by cancer and their families.
C-Further unveils first therapeutic programmes dedicated to paediatric oncology
C‑Further launches its first targeted paediatric cancer programmes, collaborating with global academic and industry partners to advance new therapeutics for Ewing sarcoma, bone sarcoma, medulloblastoma and childhood AML.
From Chemo to CAR-T: A mum’s call for Child-First Drug Design
Courtney Addison on her son Cayden's cancer journey and the need for more targeted paediatric cancer treatments in an interview with C-Further.
Podcast: Changing the Playbook on Childhood Cancers
In this episode of RAREcast, Daniel Levine, a leading voice in oncology innovation, speaks with David Jenkinson of LifeArc about C-Further and what makes it a standout model in the current paediatric cancer translational science landscape.